97 related articles for article (PubMed ID: 20151941)
1. Targeted delivery of anti-cancer growth inhibitory peptides derived from human alpha-fetoprotein: review of an International Multi-Center Collaborative Study.
Mizejewski GJ; Mirowski M; Garnuszek P; Maurin M; Cohen BD; Poiesz BJ; Posypanova GA; Makarov VA; Severin ES; Severin SE
J Drug Target; 2010 Sep; 18(8):575-88. PubMed ID: 20151941
[TBL] [Abstract][Full Text] [Related]
2. Review and proposed action of alpha-fetoprotein growth inhibitory peptides as estrogen and cytoskeleton-associated factors.
Mizejewski G; Smith G; Butterstein G
Cell Biol Int; 2004; 28(12):913-33. PubMed ID: 15566961
[TBL] [Abstract][Full Text] [Related]
3. Review of Growth Inhibitory Peptide as a biotherapeutic agent for tumor growth, adhesion, and metastasis.
Muehlemann M; Miller KD; Dauphinee M; Mizejewski GJ
Cancer Metastasis Rev; 2005 Sep; 24(3):441-67. PubMed ID: 16258731
[TBL] [Abstract][Full Text] [Related]
4. Anticancer versus antigrowth activities of three analogs of the growth-inhibitory peptide: relevance to physicochemical properties.
Mizejewski GJ; Eisele L; Maccoll R
Anticancer Res; 2006; 26(4B):3071-6. PubMed ID: 16886636
[TBL] [Abstract][Full Text] [Related]
5. Update of alpha fetoprotein growth-inhibitory peptides as biotherapeutic agents for tumor growth and metastasis.
Mizejewski GJ; Muehlemann M; Dauphinee M
Chemotherapy; 2006; 52(2):83-90. PubMed ID: 16498241
[TBL] [Abstract][Full Text] [Related]
6. Alpha-fetoprotein-mediated targeting of anti-cancer drugs to tumor cells in vitro.
Severin SE; Moskaleva EYu ; Shmyrev II; Posypanova GA; Belousova YuV ; Sologub VK; Luzhkov YuM ; Nakachian R; Andreani J; Severin ES
Biochem Mol Biol Int; 1995 Oct; 37(2):385-92. PubMed ID: 8673023
[TBL] [Abstract][Full Text] [Related]
7. Anti-prostate cancer and anti-breast cancer activities of two peptides derived from alpha-fetoprotein.
Caceres G; Dauphinee MJ; Eisele LE; MacColl R; Mizejewski GJ
Anticancer Res; 2002; 22(5):2817-20. PubMed ID: 12530002
[TBL] [Abstract][Full Text] [Related]
8. The alpha-fetoprotein-derived growth inhibitory peptide 8-mer fragment: review of a novel anticancer agent.
Mizejewski GJ
Cancer Biother Radiopharm; 2007 Feb; 22(1):73-98. PubMed ID: 17627416
[TBL] [Abstract][Full Text] [Related]
9. Survey of functional activities of alpha-fetoprotein derived growth inhibitory peptides: review and prospects.
Mizejewskia GJ; Butterstein G
Curr Protein Pept Sci; 2006 Feb; 7(1):73-100. PubMed ID: 16472170
[TBL] [Abstract][Full Text] [Related]
10. Antiestrogenic and anticancer activities of peptides derived from the active site of alpha-fetoprotein.
Joseph LC; Bennett JA; Kirschner KN; Shields GC; Hughes J; Lostritto N; Jacobson HI; Andersen TT
J Pept Sci; 2009 Apr; 15(4):319-25. PubMed ID: 19189271
[TBL] [Abstract][Full Text] [Related]
11. Isolation and structural and functional characterization of two stable peptic fragments of human alpha-fetoprotein.
Dudich I; Tokhtamysheva N; Semenkova L; Dudich E; Hellman J; Korpela T
Biochemistry; 1999 Aug; 38(32):10406-14. PubMed ID: 10441135
[TBL] [Abstract][Full Text] [Related]
12. Alpha-fetoprotein growth inhibitory peptides: potential leads for cancer therapeutics.
Mizejewski GJ; MacColl R
Mol Cancer Ther; 2003 Nov; 2(11):1243-55. PubMed ID: 14617798
[TBL] [Abstract][Full Text] [Related]
13. The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells.
Huq A; Singh B; Meeker T; Mascarenhas D
Anticancer Drugs; 2009 Jan; 20(1):21-31. PubMed ID: 19342998
[TBL] [Abstract][Full Text] [Related]
14. The receptor binding fragment of alpha-fetoprotein is a promising new vector for the selective delivery of antineoplastic agents.
Posypanova GA; Makarov VA; Savvateeva MV; Bereznikova AV; Severin ES
J Drug Target; 2013 May; 21(5):458-65. PubMed ID: 23600748
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of intracellular delivery of anti-cancer drugs by the Tat peptide.
Zhao JF; Chen JY; Mi L; Wang PN; Peng Q
Ultrastruct Pathol; 2011 May; 35(3):119-23. PubMed ID: 21405950
[TBL] [Abstract][Full Text] [Related]
16. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models.
Verma B; Neethling FA; Caseltine S; Fabrizio G; Largo S; Duty JA; Tabaczewski P; Weidanz JA
J Immunol; 2010 Feb; 184(4):2156-65. PubMed ID: 20065111
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
18. High-efficient expression, refolding and purification of functional recombinant C-terminal fragment of human alpha-fetoprotein.
Sharapova OA; Pozdnykova NV; Laurinavichyute DK; Yurkova MS; Posypanova GA; Fedorov AN; Severin SE; Severin ES
Protein Expr Purif; 2010 Sep; 73(1):31-5. PubMed ID: 20363333
[TBL] [Abstract][Full Text] [Related]
19. Proliferation of human breast cancer cells and anti-cancer action of doxorubicin and vinblastine are independent of PKC-alpha.
Liu DS; Krebs CE; Liu SJ
J Cell Biochem; 2007 May; 101(2):517-28. PubMed ID: 17171646
[TBL] [Abstract][Full Text] [Related]
20. Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs.
Liu SQ; Wiradharma N; Gao SJ; Tong YW; Yang YY
Biomaterials; 2007 Mar; 28(7):1423-33. PubMed ID: 17141308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
